Cellectar Biosciences (NASDAQ:CLRB) ran up 28% in premarket this morning on strong volume after the company announced positive Phase 1 Trial results from its lead PDC compound, CLR 131.CLRB has been on a slide to the downside since mid-March, but … Read Full Story
Recent Biotech Stories
Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance
MADISON, Wis., Aug. 14, 2017 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces financial results for the second quarter of 2017. Management will host a teleconference and live webcast to review these results, including a review of corporate performance, at 5:00 PM ET today. Summary of […]
Pieris Pharmaceuticals Appoints Allan Reine, M.D., as Chief Financial Officer
BOSTON, MA–(Marketwired – August 10, 2017) – Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced that it has appointed Allan Reine as Senior Vice President and Chief Financial Officer, effective yesterday, August 9, 2017. Dr. Reine is an […]
Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2017 and Provides Corporate Update
BOSTON, MA–(Marketwired – August 09, 2017) – Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, today reported financial results for the second quarter of 2017 and provided an update on the Company’s recent developments, including: Strategic alliance in respiratory […]